Electromed, Inc. Announces Share Repurchase Authorization

Rhea-AI Summary

Electromed (NYSE American: ELMD) announced that its board of directors has authorized a new share repurchase program of up to $5.0 million of common stock on March 6, 2025. The company, which specializes in innovative airway clearance technologies, will execute the buyback through various means including open market purchases, private transactions, and block trades, depending on market conditions.

Management will determine the timing and volume of repurchases based on market conditions and other factors. The board will periodically review and may modify the authorization's terms and size. CEO Jim Cunniff stated that this initiative demonstrates confidence in their business strength and commitment to creating shareholder value while maintaining financial flexibility for future growth investments.

Positive

• Authorization of $5.0 million share repurchase program
• Company has excess cash reserves available for buyback
• Maintains strong balance sheet while returning capital to shareholders
• Financial flexibility preserved for future growth investments

Negative

• Reduction in cash reserves available for other strategic initiatives

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that on March 6, 2025, its board of directors authorized the repurchase of up to $5.0 million of Electromed common stock.

The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. Electromed’s board of directors expects to review the share repurchase authorization periodically and may approve changes to its terms and size.

“I am excited to announce Electromed’s next share repurchase authorization, which reflects our confidence in the strength of our business. Our management team and Board are committed to creating additional shareholder value. We believe deploying our excess cash reserves to opportunistically buy back stock helps us to return capital to our shareholders while maintaining both a strong balance sheet and the financial flexibility to invest in future growth opportunities,” said Jim Cunniff, President, and Chief Executive Officer.

About Electromed, Inc.

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. Electromed is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release, including the prospect of future repurchases of Electromed’s equity securities, potential benefits of the same, and Electromed’s financial position, constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “estimate,” “continue,” “expect,” “intend,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; alternative capital deployment opportunities; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250310991714/en/

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Healthcare

(617) 877-9641

mike.cavanaugh@icrhealthcare.com

Source: Electromed, Inc.

FAQ

How much is Electromed's (ELMD) new share repurchase authorization worth?

Electromed's board authorized a share repurchase program worth up to $5.0 million on March 6, 2025.

How will Electromed (ELMD) execute its share repurchase program?

The company will execute repurchases through open market purchases, privately negotiated transactions, and block trades, based on market conditions.

When does Electromed's (ELMD) share repurchase program begin?

The authorization was announced on March 6, 2025, with timing of actual repurchases to be determined by management based on market conditions.

What is the purpose of Electromed's (ELMD) share buyback program?

The program aims to return capital to shareholders while maintaining financial flexibility for growth opportunities, reflecting management's confidence in the business.